HRMY Harmony Biosciences Holdings Inc
Price (delayed)
$32.72
Market cap
$1.88B
P/E Ratio
12.78
Dividend/share
N/A
EPS
$2.56
Enterprise value
$1.6B
Harmony Biosciences Holdings, Inc. operates as a pharmaceutical company. The Company focuses on the research, drug development, and treatment for neurologic disorder of sleep-wake state instability. Harmony Biosciences Holdings serves
Highlights
The stock's price to earnings (P/E) is 56% less than its 5-year quarterly average of 28.9 and 17% less than its last 4 quarters average of 15.4
Harmony Biosciences Holdings's equity has increased by 41% YoY and by 10% from the previous quarter
Key stats
What are the main financial stats of HRMY
Market
Valuations
Earnings
Shares outstanding
57.35M
Market cap
$1.88B
Enterprise value
$1.6B
Price to earnings (P/E)
12.78
Price to book (P/B)
2.83
Price to sales (P/S)
2.6
EV/EBIT
7.66
EV/EBITDA
6.87
EV/Sales
2.24
Revenue
$714.73M
Gross profit
$557.92M
Operating income
$190.83M
Net income
$145.49M
EBIT
$209.3M
EBITDA
$233.41M
Free cash flow
$218.67M
Per share
Balance sheet
Liquidity
EPS
$2.56
EPS diluted
$2.51
Free cash flow per share
$3.84
Book value per share
$11.56
Revenue per share
$12.56
TBVPS
$15.57
Total assets
$999.2M
Total liabilities
$340.05M
Debt
$179.27M
Equity
$659.16M
Working capital
$404.17M
Debt to equity
0.27
Current ratio
3.31
Quick ratio
3.14
Net debt/EBITDA
-1.17
Margins
Efficiency
Dividend
EBITDA margin
32.7%
Gross margin
78.1%
Net margin
20.4%
Operating margin
26.7%
Return on assets
16%
Return on equity
25.2%
Return on invested capital
47.7%
Return on capital employed
25.4%
Return on sales
29.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
HRMY stock price
How has the Harmony Biosciences Holdings stock price performed over time
Intraday
-2.62%
1 week
-2.94%
1 month
-16.26%
1 year
9.32%
YTD
-4.91%
QTD
-4.91%
Financial performance
How have Harmony Biosciences Holdings's revenue and profit performed over time
Revenue
$714.73M
Gross profit
$557.92M
Operating income
$190.83M
Net income
$145.49M
Gross margin
78.1%
Net margin
20.4%
The company's revenue rose by 23% YoY and by 4.8% QoQ
The gross profit has grown by 21% YoY and by 4% from the previous quarter
Harmony Biosciences Holdings's net income has increased by 19% from the previous quarter and by 13% YoY
The operating margin has declined by 19% year-on-year but it rose by 3.9% since the previous quarter
Growth
What is Harmony Biosciences Holdings's growth rate over time
Valuation
What is Harmony Biosciences Holdings stock price valuation
P/E
12.78
P/B
2.83
P/S
2.6
EV/EBIT
7.66
EV/EBITDA
6.87
EV/Sales
2.24
The stock's price to earnings (P/E) is 56% less than its 5-year quarterly average of 28.9 and 17% less than its last 4 quarters average of 15.4
Harmony Biosciences Holdings's EPS has increased by 19% QoQ and by 18% YoY
The stock's price to book (P/B) is 71% less than its 5-year quarterly average of 9.6 and 17% less than its last 4 quarters average of 3.4
Harmony Biosciences Holdings's equity has increased by 41% YoY and by 10% from the previous quarter
HRMY's P/S is 55% below its 5-year quarterly average of 5.8 and 10% below its last 4 quarters average of 2.9
The company's revenue rose by 23% YoY and by 4.8% QoQ
Efficiency
How efficient is Harmony Biosciences Holdings business performance
Harmony Biosciences Holdings's return on sales has decreased by 14% YoY but it has increased by 3.2% QoQ
HRMY's return on assets is up by 13% since the previous quarter but it is down by 4.8% year-on-year
The ROE is up by 9% from the previous quarter but it is down by 8% YoY
HRMY's return on invested capital is down by 6% year-on-year but it is up by 6% since the previous quarter
Dividends
What is HRMY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for HRMY.
Financial health
How did Harmony Biosciences Holdings financials performed over time
HRMY's total assets is 194% greater than its total liabilities
HRMY's total assets is up by 23% year-on-year and by 8% since the previous quarter
The current ratio has grown by 20% YoY and by 2.2% from the previous quarter
The debt is 73% less than the equity
Harmony Biosciences Holdings's equity has increased by 41% YoY and by 10% from the previous quarter
The debt to equity has declined by 34% year-on-year and by 13% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.